Latest filing published 29 Nov 2017 for UroGen Pharma Ltd., €1.1M.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
ProQuest Investments IV, L.P.: trading record in brief
Filings by ProQuest Investments IV, L.P. span 3 companies, the busiest being Eagle Pharmaceuticals, Inc., Immune Design Corp. and UroGen Pharma Ltd. In total, 131 filings cover trades dated from 29 July 2014 to 28 November 2017.
The open-market side counts 1 purchase for €3.5M alongside 115 sales for €110.9M. On balance, insiders were net sellers of €107.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 9 option exercises. Since January 2017: no purchases and 20 sales on the market.
The record was last updated on 29 November 2017 with an open-market sale (€1.1M) in UroGen Pharma Ltd. The last insider purchase was made public on 31 July 2014, 4,483 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to ProQuest Investments IV, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 31,491 shares@ US$41.1215.2% of flowOrdinary Shares, par value NIS 0.01 per shareSEC:0000932440-17-000088:0
- 177,807 shares@ US$40.5184.8% of flowOrdinary Shares, par value NIS 0.01 per shareSEC:0000932440-17-000088:1
- 3,584,087 shares0Common Stock $0.001 par valueSEC:0000932440-17-000039:0
- 149,107 shares0Common Stock $0.001 par valueSEC:0000932440-17-000039:1
- 149,107 shares0Common Stock $0.001 par valueSEC:0000932440-17-000039:2
- 3,120 shares@ US$4.4251.6% of flowCommon Stock $0.001 par valueSEC:0000932440-17-000034:5
- 2,340 shares@ US$0.907.9% of flowCommon Stock $0.001 par valueSEC:0000932440-17-000034:0
- 2,340 shares@ US$4.0435.4% of flowCommon Stock $0.001 par valueSEC:0000932440-17-000034:1
- 2,340 shares@ US$8.78Common Stock $0.001 par valueSEC:0000932440-17-000034:2
- 9,360 shares@ US$12.67Common Stock $0.001 par valueSEC:0000932440-17-000034:6
- 10,000 shares@ US$46.09Common Stock $0.001 par valueSEC:0000932440-17-000034:7
- 20,000 shares@ US$59.31Common Stock $0.001 par valueSEC:0000932440-17-000034:8
- 51,219 shares@ US$88.34Common Stock $0.001 par valueSEC:0000932440-17-000034:9
- 2,961 shares@ US$89.09Common Stock $0.001 par valueSEC:0000932440-17-000034:10
- 6,223 shares@ US$83.00Common Stock $0.001 par valueSEC:0000932440-17-000032:0
- 23,689 shares@ US$83.02Common Stock $0.001 par valueSEC:0000932440-17-000032:1
- 61,420 shares@ US$83.13Common Stock $0.001 par valueSEC:0000932440-17-000032:2
- 37,731 shares@ US$83.00Common Stock $0.001 par valueSEC:0000932440-17-000030:0
- 6,182 shares@ US$83.02Common Stock $0.001 par valueSEC:0000932440-17-000030:1
- 58,755 shares@ US$83.01Common Stock $0.001 par valueSEC:0000932440-17-000030:2
- 400 shares@ US$83.000.3% of flowCommon Stock $0.001 par valueSEC:0000932440-17-000030:3
- 500 shares@ US$83.010.3% of flowCommon Stock $0.001 par valueSEC:0000932440-17-000030:4
- 500 shares@ US$83.100.3% of flowCommon Stock $0.001 par valueSEC:0000932440-17-000020:0
- 700 shares@ US$83.010.3% of flowCommon Stock $0.001 par valueSEC:0000932440-17-000020:1
- 9,120 shares@ US$82.08Common Stock $0.001 par valueSEC:0000932440-17-000018:0
25 of 121 declarations
